w a significant reduction of sodium in foods and beverages yet maintain the salty taste desirable to consumers. This program is an important research focus for the Company's longer-term pipeline.
Senomyx is analyzing a proprietary database of proteins found in taste buds to determine the role of a number of proteins that may be relevant to salt taste perception. The current focus is on targeted analytical approaches to identify specific proteins that could be viable candidates for the receptors or co-factors responsible for salt taste. Taste bud proteins under investigation include potential lead candidates for the salt taste receptor, as well as proteins that may be involved in the process for signaling the sensory perception of saltiness.
Intellectual Property: Senomyx continues to be diligent in seeking protection for its intellectual property. As of September 30, 2013, the Company is the owner or exclusive licensee of 396 issued patents and several hundred pending patent applications in the U.S., Europe, and elsewhere related to proprietary taste science technologies.
Financial Review:At September 30, 2013, Senomyx held $35.6 million in cash, cash equivalents and investments available-for-sale.
Total revenues were $6.7 million for the quarter ended September 30, 2013, compared to $7.9 million for the quarter ended September 30, 2012. Total revenues for the nine months ended September 30, 2013 were $21.9 million, compared to $23.1 million for the nine months ended September 30, 2012.
Development revenues were $5.9 million in the third quarter of 2013 and $7.0 million in the third quarter of 2012. Development revenues were $18.1 million and $20.2 million for the nine months ended September 30, 2013 and 2012, respectively. These changes are primarily due to one-time development milestones earned in 2012, including $1.3 million related to our Sweet TasPage: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Related biology technology :1
. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference2
. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy3
. SENOMYX AND FIRMENICH ANNOUNCE AMENDMENT OF THEIR SWEET TASTE PROGRAM AGREEMENT4
. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 12TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE5
. SENOMYX ANNOUNCES CORPORATE UPDATE AND FIRST QUARTER FINANCIAL RESULTS6
. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE7
. SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER FINANCIAL RESULTS8
. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE MIDWEST IDEAS INVESTOR CONFERENCE9
. Senomyx Announces Management Update10
. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting11
. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations